Therapeutic Options for „Slow‑ go“ Patients with Chronic Lymphocytic Leukemia

Česká verzia

Authors: L. Smolej
Authors place of work: IV. interní hematologická klinika LF UK a FN Hradec Králové
Published in the journal: Klin Onkol 2015; 28(Supplementum 3): 30-38
doi: https://doi.org/10.14735/amko20153S30

Summary

Chronic lymphocytic leukemia is a disease of older patients, most of them suffering from significant comorbidities or functional limitations (so‑ called ’slow‑ go’ patients). Unfortunately, clinical trials in chronic lymphocytic leukemia have until recently focused mainly on the subgroup of younger patients in good overall condition (‘go‑ go’ patients). Clinico‑ biological parameters, such as performance status, calculated creatinine clearance, the number and severity of comorbidities along with individual clinical assessment can help guide decisions relating to the objectives and ultimately the intensity of treatment. Two large randomized studies have recently demonstrated that the addition of monoclonal antibodies against CD20 (obinutuzumab, rituximab and ofatumumab) to chlorambucil in untreated ‘slow‑ go’ patients resulted in a significant increase in the number of complete remissions, progression‑free survival and even overall survival (for obinutuzumab and rituximab) with an acceptable safety profile. Chemoimmunotherapy combining chlorambucil with anti‑CD20 antibody is thus the new standard 1^st line therapy in this group of patients. Treatment of relapsed/ refractory chronic lymphocytic leukemia in ‘slow‑ go’ patients is very difficult and specific data is sparse. In this indication, we have witnessed an extraordinary breakthrough by means of small oral inhibitors interfering with B‑ cell receptor downstream signaling pathways: ibrutinib, the Bruton‘s tyrosine kinase inhibitor, and idelalisib, the inhibitor of phosphatidylinositol 3- kinase δ. Both drugs radically changed the approach to the treatment of relapsed/ refractory chronic lymphocytic leukemia; relatively mild toxicity also predetermines their use in elderly/ comorbid patients. Other treatment options for relapsed/ refractory chronic lymphocytic leukemia in this subgroup include alemtuzumab, ofatumumab, high‑dose glucocorticoids + antiCD20 antibodies, or bendamustine + rituximab regimen. This review summarizes current data regarding the treatment of elderly and comorbid patients with chronic lymphocytic leukemia.

Key words:
chronic lymphocytic leukemia – comorbidity – geriatric assessment – obinutuzumab – rituximab – ofatumumab – ibrutinib – idelalisib

This work was supported by the grant IGA MH CZ NT13412-4/2012, MH CZ – DRO (UHHK, 00179906) and by the programme PRVOUK P37/08.

I declare that, in connection with the above-mentioned contribution, which I am an author, I have a conflict of interest with the typed the following companies: Roche, Janssen-Cilag , Gilead and GlaxoSmithKline (honoraria for lectures or consultations, travel grants).

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
23. 7. 2015

Accepted:
29. 7. 2015

Zdroje

1. Dores GM, Anderson WF, Curtis RE et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007; 139(5): 809– 819.

2. Linet MS, Schubauer‑ Berigan MK, Weisenburger DD et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol 2007; 139(5): 672– 686.

3. Pfeil AM, Imfeld P, Pettengell R et al. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol 2015; 94(3): 421– 429. doi: 10.1007/ s00277‑ 014‑ 2217‑ 7.

4. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46(2): 219– 234.

5. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48(1): 198– 206.

6. Abrisqueta P, Pereira A, Rozman C et al. Improving survival in patients with chronic lymphocytic leukemia (1980– 2008): the Hospital Clinic of Barcelona experience. Blood 2009; 114(10): 2044– 2050. doi: 10.1182/ blood‑ 2009‑ 04‑ 214346.

7. Panovska A, Doubek M, Brychtova Y et al. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk 2010; 10(4): 297– 300. doi: 10.3816/ CLML.2010.n.061.

8. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21(1): 12– 17.

9. Dreger P, Schetelig J, Andersen N et al. Managing high‑risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014; 124(26): 3841– 3849. doi: 10.1182/ blood‑ 2014‑ 07‑ 586826.

10. Hallek M, Fischer K, Fingerle‑ Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open‑ label, phase 3 trial. Lancet 2010; 376(9747): 1164– 1174. doi: 10.1016/ S0140‑ 6736(10)61381‑ 5.

11. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86(12): 2684– 2692.

12. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 2001; 86(1): 8– 12.

13. Robak T, Dmoszynska A, Solal‑ Celigny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression‑free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1756– 1765. doi: 10.1200/ JCO.2009.26.4556.

14. Mabed M, Aref S, Fouda M et al. Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B‑ cell chronic lymphatic leukemia. Leuk Lymphoma 2004; 45(10): 2029– 2035.

15. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first‑line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107(3): 885– 891.

16. Robak T, Blonski JZ, Gora‑ Tybor J et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 2006; 108(2): 473– 479.

17. Catovsky D. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370(9583): 230– 239.

18. Flinn IW. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25(7): 793– 798.

19. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first‑line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25(35): 5616– 5623.

20. Eichhorst BF, Busch R, Stilgenbauer S et al. First‑line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114(16): 3382– 3391. doi: 10.1182/ blood‑ 2009‑ 02‑ 206185.

21. Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27(26): 4378– 4384. doi: 10.1200/ JCO.2008.20.8389.

22. O‘Brien S, Moore JO, Boyd TE et al. 5‑year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27(31): 5208– 5212. doi: 10.1200/ JCO.2009.22.5748.

23. Robak T, Jamroziak K, Gora‑ Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first‑line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG‑ CLL3 Study). J Clin Oncol 2010; 28(11): 1863– 1869. doi: 10.1200/ JCO.2009.25.9630.

24. Sutton L, Chevret S, Tournilhac O et al. Autologous stem cell transplantation as a first‑line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM‑ TC and GFLLC. Blood 2011; 117(23): 6109– 6119. doi: 10.1182/ blood‑ 2010‑ 11‑ 317073.

25. Elter T, Gercheva‑ Kyuchukova L, Pylylpenko H et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011; 12(13): 1204– 1213. doi: 10.1016/ S1470‑ 2045(11)70242‑ X.

26. Reynolds C, Di Bella N, Lyons RM et al. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B‑ cell chronic lymphocytic leukemia. Invest New Drugs 2012; 30(3): 1232– 1240. doi: 10.1007/ s10637‑ 011‑ 9737‑ y.

27. Lepretre S, Aurran T, Mahé B et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119(22): 5104– 5110. doi: 10.1182/ blood‑ 2011‑ 07‑ 365437.

28. Niederle N, Megdenberg D, Balleisen L et al. Bendamustine compared to fludarabine as second‑line treatment in chronic lymphocytic leukemia. Ann Hematol 2013; 92(5): 653– 660. doi: 10.1007/ s00277‑ 012‑ 1660‑ 6.

29. Shvidel L, Shtalrid M, Bairey O et al. Conventional dose fludarabine‑based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44(11): 1947– 1950.

30. Ferrajoli A, O’Brien S, Wierda W et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005; 46 (Suppl 1): S86: abstr. P95.

31. Wierda WG, O‘Brien S, Wang X et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109(11): 4679– 4985.

32. Thurmes P, Call T, Slager S et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008; 49(1): 49– 56. doi: 10.1080/ 10428190701724785.

33. Wierda WG, O‘Brien S, Wang X et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009; 27(10): 1637– 1643. doi: 10.1200/ JCO.2008.18.1701.

34. Shanafelt TD, Jenkins G, Call TG et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009; 115(2): 363– 372. doi: 10.1002/ cncr.24004.

35. Pflug N, Bahlo J, Shanafelt TD et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124(1): 49– 62. doi: 10.1182/ blood‑ 2014‑ 02‑ 556399.

36. Goede V, Cramer P, Busch R et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica 2014; 99(6): 1095– 1100. doi: 10.3324/ haematol.2013.096792.

37. Lindeman RD. Changes in renal function with aging. Implications for treatment. Drugs Aging 1992; 2(5): 423– 431.

38. Fliser D. Ren sanus in corpore sano: the myth of the inexorable decline of renal function with senescence. Nephrol Dial Transplant 2005; 20(3): 482– 485.

39. Presta P, Lucisano G, Fuiano L et al. The kidney and the elderly: why does the risk increase? Int Urol Nephrol 2012; 44(2): 625– 632. doi: 10.1007/ s11255‑ 011‑ 0063‑ 2.

40. Plunkett W, Gandhi V, Huang P et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20 (5 Suppl 7):2– 12.

41. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20(3): 194– 208.

42. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31– 41.

43. Martell RE, Peterson BL, Cohen HJ et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002; 50(1): 37– 45.

44. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital‑based cancer registry. JAMA 2004; 291(20): 2441– 2447.

45. Janssen‑ Heijnen ML, van Spronsen DJ, Lemmens VE et al. A population‑based study of severity of comorbidity among patients with non‑Hodgkin‘s lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005; 129(5): 597– 606.

46. Kobayashi Y, Miura K, Hojo A et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B‑ cell lymphoma. J Cancer Res Clin Oncol 2011; 137(7): 1079– 1084. doi: 10.1007/ s00432‑ 010‑ 0973‑ x.

47. Wieringa A, Boslooper K, Hoogendoorn M et al. Comorbidity is an independent prognostic factor in patients with advanced‑stage diffuse large B‑ cell lymphoma treated with R‑ CHOP: a population‑based cohort study. Br J Haematol 2014; 165(4): 489– 496. doi: 10.1111/ bjh.12765.

48. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute‑ Working Group 1996 guidelines. Blood 2008; 111(12): 5446– 5456. doi: 10.1182/ blood‑ 2007‑ 06‑ 093906.

49. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute‑ sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diag-nosis and treatment. Blood 1996; 87(12): 4990– 4997.

50. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia‑ what do we need to know? Nat Rev Clin Oncol 2011; 8(1): 38– 47. doi: 10.1038/ nrclinonc.2010.167.

51. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25(14): 1824– 1831.

52. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16(5): 622– 626.

53. Parmelee PA, Thuras PD, Katz IR et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995; 43(2): 130– 137.

54. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16(4): 1582– 1587.

55. Wedding U, Rohrig B, Klippstein A et al. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007; 133(12): 945– 950.

56. Nabhan C, Smith SM, Helenowski I et al. Analysis of very elderly (≥80 years) non‑hodgkin lymphoma: impact of functional status and co‑ morbidities on outcome. Br J Haematol 2012; 156(2): 196– 204. doi: 10.1111/ j.1365‑ 2141.2011.08934.x.

57. Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370(12): 1101– 1110. doi: 10.1056/ NEJMoa1313984.

58. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373– 383.

59. Sarfati D. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 2012; 65(9): 924– 933. doi: 10.1016/ j.jclinepi.2012.02.017.

60. Lin TL, Kuo MC, Shih LY et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 2012; 91(9): 1383– 1391. doi: 10.1007/ s00277‑ 012‑ 1463‑ 9.

61. Holzner B, Kemmler G, Kopp M et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 2004; 72(6): 381– 389.

62. Else M, Smith AG, Cocks K et al. Patients‘ experience of chronic lymphocytic leukaemia: baseline health‑related quality of life results from the LRF CLL4 trial. Br J Haematol 2008; 143(5): 690– 697. doi: 10.1111/ j.1365‑ 2141.2008.07407.x.

63. Shanafelt TD, Bowen D, Venkat C et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007; 139(2): 255– 264.

64. Eichhorst BF, Busch R, Obwandner T et al. Health‑related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first‑line therapy: a study by the German CLL Study Group. J Clin Oncol 2007; 25(13): 1722– 1731.

65. Else M, Cocks K, Crofts S et al. Quality of life in chronic lymphocytic leukemia: 5‑year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma 2012; 53(7): 1289– 1298. doi: 10.3109/ 10428194.2011.649479.

66. Pashos CL, Flowers CR, Kay NE et al. Association of health‑related quality of life with gender in patients with B‑ cell chronic lymphocytic leukemia. Support Care Cancer 2013; 21(10): 2853– 2860. doi: 10.1007/ s00520‑ 013‑ 1854‑ z.

67. van den Broek EC, Oerlemans S, Nijziel MR et al. Impact of active surveillance, chlorambucil, and other therapy on health‑related quality of life in patients with CLL/ SLL in the Netherlands. Ann Hematol 2015; 94(1): 45– 56. doi: 10.1007/ s00277‑ 014‑ 2161‑ 6.

68. Altman SJ, Haut A, Cartwright GE et al. Early experience with p‑ (N, N‑ di‑ 2- chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia. Cancer 1956; 9(3): 512– 517.

69. Hillmen P, Gribben JG, Follows GA et al. Rituximab plus chlorambucil as first‑line treatment for chronic lymphocytic leukemia: Final analysis of an open‑ label phase II study. J Clin Oncol 2014; 32(12): 1236– 1241. doi: 10.1200/ JCO.2013.49.6547.

70. Catovsky D, Else M, Richards S. Chlorambucil – still not bad: a reappraisal. Clin Lymphoma Myeloma Leuk 2011; 11 (Suppl 1): S2– S6. doi: 10.1016/ j.clml.2011.02.006.

71. Hillmen P, Robat T, Janssens A et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III Study Complement 1 (OMB110911). ASH Annual Meeting abstracts. Blood 2013; 122(21): 528.

72. Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30(26): 3209– 3216. doi: 10.1200/ JCO.2011.39.2688.

73. Marotta G, Bigazzi C, Lenoci M et al. Low‑dose fludarabine and cyclophosphamide in elderly patients with B‑ cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85(12): 1268– 1270.

74. Forconi F, Fabbri A, Lenoci M et al. Low‑dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic. Leukaemia Hematol Oncol 2008; 26(4): 247– 251. doi: 10.1002/ hon.868.

75. Smolej L, Brychtova Y, Doubek M et al. Low‑dose FCR is a safe and effective treatment option for elderly/ comorbid patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma. Updated Results of Project Q‑ Lite By Czech CLL Study Group. ASH Annual Meeting Abstracts. Blood 2014; 124(21): 4670.

76. Mulligan SP, Gill D, Turner P et al. A Randomised dose De‑ Escalation Study of oral fludarabine ± oral cyclophosphamide and intravenous rituximab as first‑line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years: final analysis of response and toxicity. ASH Annual Meeting Abstracts. Blood 2014; 124(21): 3325.

77. Keating MJ, O‘Brien S, Kontoyiannis D et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43(9): 1755– 1762.

78. Keating MJ. Therapeutic role of alemtuzumab (Campath‑ 1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99(10): 3554– 3561.

79. Fiegl M, Stauder R, Steurer M et al. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol 2014; 93(2): 267– 277. doi: 10.1007/ s00277‑ 013‑ 1966‑ z.

80. Tam CS, O‘Brien S, Lerner S et al. The natural history of fludarabine‑ refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007; 48(10): 1931– 1939.

81. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single‑agent CD20 immunotherapy in fludarabine‑ refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1749– 1755. doi: 10.1200/ JCO.2009.25.3187.

82. Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/ or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29(26): 3559– 3566. doi: 10.1200/ JCO.2010.33.8061.

83. Bowen DA, Call TG, Jenkins GD et al. Methylprednisolone‑ rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48(12): 2412– 2417.

84. Pileckyte R, Jurgutis M, Valceckiene V et al. Dose‑dense high‑dose methylprednisolone and rituximab in the treatment of relapsed or refractory high‑risk chronic lymphocytic leukemia. Leuk Lymphoma 2011; 52(6): 1055– 1065. doi: 10.3109/ 10428194.2011.562572.

85. Šimkovič M, Motyčková M, Belada D et al. Five years of experience with rituximab plus high‑dose dexamethasone for relapsed/ refractory chronic lymphocytic leukemia. Arch Med Sci. In press 2016; 12: (2).

86. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369(1): 32– 42. doi: 10.1056/ NEJMoa1215637.

87. Byrd JC, Brown JR, O‘Brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371(3): 213– 223. doi: 10.1056/ NEJMoa1400376.

88. Brown JR, Byrd JC, Coutre SE et al. Idelalisib, an inhibitor of phosphatidylinositol 3- kinase p110δ, for relapsed/ refractory chronic lymphocytic leukemia. Blood 2014; 123(22): 3390– 3397. doi: 10.1182/ blood‑ 2013‑ 11‑ 535047.

89. Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370(11): 997– 1007. doi: 10.1056/ NEJMoa1315226.

90. ClinicalTrials.gov [homepage on the Internet]. Chronic lymphocytic leukemia. [cited 2015 July 20]. Available from: http:/ / clinicaltrials.gov/ ct2/ results?term=chronic+lymphocytic+leukemia&recr=Open&no_unk=Y&type=Intr&phase=12&pg=1.